search
Back to results

Transcutaneous Intercostal Nerve Stimulation in Spinal Cord Injury (TINS)

Primary Purpose

Neuropathic Pain, SCI - Spinal Cord Injury

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
TINS Active protocol
Sham protocol
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuropathic Pain

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Acute tSCI paraplegia within 4 weeks of injury (n=22)
  • 18-75 years old
  • Neurologic levels T1-T10
  • English speaking
  • Admitted to TIRR with pain medications
  • TINS can elicit visible or palpable abdominal muscle contraction

Exclusion Criteria:

  • Subjects with pacemakers, defibrillators, insulin pumps, and similar devices
  • History of peripheral neuropathy
  • History of premorbid symptoms of peripheral neuropathy (numbness and/or tingling in the lower extremities, sharp/jabbing/burning pain in the lower extremities, sensitivity to touch, lack of coordination, lack of sensation, muscle weakness, etc.)
  • History of nervous system disorder (i.e. prior SCI, stroke, brain injury, degenerative diseases such as Parkinson's disease, etc.)
  • Ventilator dependent respiration
  • Inability to speak
  • Non-English speakers
  • Pregnancy
  • History of chronic pain
  • Intolerant to electric stimulation
  • Intolerant to the trial sessions

Sites / Locations

  • The University of Texas Health Science Center at Houston

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

TINS Active

Sham protocol

Arm Description

Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.

Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.

Outcomes

Primary Outcome Measures

Number of participants with morbidity as measured by infections
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections
Number of participants with morbidity as measured by infections
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections.
Number of participants with morbidity as measured by infections
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections.
Number of participants with morbidity as measured by burns.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Number of participants with morbidity as measured by burns.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Number of participants with morbidity as measured by burns.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Number of participants with morbidity as measured by urgent transfers.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Number of participants with morbidity as measured by urgent transfers.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Number of participants with morbidity as measured by urgent transfers.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Number of participants with morbidity as measured by spasticity scores per usual care.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care
Number of participants with morbidity as measured by spasticity scores per usual care.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care
Number of participants with morbidity as measured by spasticity scores per usual care.
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care

Secondary Outcome Measures

Number of participants with improved spasiticy scores as measured by PENN SPASM FREQUENCY SCALE (PSFS)
Contains clinically relevant core questions concerning SCI-related pain. This is a 2 component self-report measure of the frequency of reported muscle spasms which is commonly used to quantify spasticity. Developed to augment clinical ratings of spasticity and provide a more comprehensive understanding of an individual's spasticity status. The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe". The second component is not answered if the person indicates they have no spasms in part. Lower scores indicate better outcomes.
Number of participants with improved spasiticy scores as measured by PENN SPASM FREQUENCY SCALE (PSFS)
Contains clinically relevant core questions concerning SCI-related pain. This is a 2 component self-report measure of the frequency of reported muscle spasms which is commonly used to quantify spasticity. Developed to augment clinical ratings of spasticity and provide a more comprehensive understanding of an individual's spasticity status. The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe". The second component is not answered if the person indicates they have no spasms in part. Lower scores indicate better outcomes.
Number of participants with decreased pain medication dosage compared at discharge and 2-month follow-up.
Compare number of participants with decreased pain medication dosage at discharge and 2-month follow-up.
Number of participants with decreased pain medication dosage compared at discharge and 2-month follow-up.
Compare number of participants with decreased pain medication dosage at discharge and 2-month follow-up.

Full Information

First Posted
July 16, 2020
Last Updated
October 15, 2021
Sponsor
The University of Texas Health Science Center, Houston
search

1. Study Identification

Unique Protocol Identification Number
NCT04506099
Brief Title
Transcutaneous Intercostal Nerve Stimulation in Spinal Cord Injury
Acronym
TINS
Official Title
Transcutaneous Intercostal Nerve Stimulation in Spinal Cord Injury
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of study staff
Study Start Date
July 17, 2020 (Actual)
Primary Completion Date
September 30, 2021 (Anticipated)
Study Completion Date
November 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the safety, feasibility, and effectiveness of electric stimulation of the nerves along the intercostal nerves on pain and spasticity in spinal cord injury patients.
Detailed Description
Neuromodulation techniques are safely used as a treatment for neuropathic pain in chronic SCI. Neuromodulation techniques have also been safely and successfully used to strengthen the abdomen in stroke patients.10 Most similar to our TINS protocol is transcutaneous tibial nerve stimulation (TTNS), which has shown to mitigate the development of neurogenic bladder in acute SCI.6 However, neuromodulation is rarely performed in acute SCI, and, to our knowledge, neuromodulation has not been performed to prevent the development of chronic neuropathic pain. There has been little published regarding the effects of electric stimulation upon the trunk in acute SCI as a prevention for chronic neuropathic pain and spasticity. Gaps in the knowledge which we intend to fill are: Safety and feasibility of TINS in acute SCI during inpatient rehabilitation. Effectiveness of a 2-week TINS protocol in acute SCI based on changes between admission, discharge, and weekly numerical pain scores and spasticity questionnaire scores in those with TINS compared to sham TINS for 2-months. Analysis of neuropathic pain medication dosages in those with and without TINS at admission, discharge, and 2 months post-discharge, and evaluation of morbidity at 2- months post-discharge

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuropathic Pain, SCI - Spinal Cord Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized sham-controlled trial
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Study participants will be blinded to the stimulation parameters of the TINS. The research assistant/investigator will apply the electrodes and the PI will be blinded the stimulation setting as well. Unblinding is expected to occur after the 2 month follow up, at which point both subject and PI will be made aware of their group assignment.
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TINS Active
Arm Type
Active Comparator
Arm Description
Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
Arm Title
Sham protocol
Arm Type
Sham Comparator
Arm Description
Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
Intervention Type
Device
Intervention Name(s)
TINS Active protocol
Intervention Description
Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
Intervention Type
Device
Intervention Name(s)
Sham protocol
Intervention Description
Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
Primary Outcome Measure Information:
Title
Number of participants with morbidity as measured by infections
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections
Time Frame
Admission
Title
Number of participants with morbidity as measured by infections
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections.
Time Frame
4-weeks post injury
Title
Number of participants with morbidity as measured by infections
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking infections.
Time Frame
2-month follow-up
Title
Number of participants with morbidity as measured by burns.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Time Frame
Admission
Title
Number of participants with morbidity as measured by burns.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Time Frame
4-weeks post injury
Title
Number of participants with morbidity as measured by burns.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking burns.
Time Frame
2-month follow-up
Title
Number of participants with morbidity as measured by urgent transfers.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Time Frame
Admission
Title
Number of participants with morbidity as measured by urgent transfers.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Time Frame
4-weeks post injury
Title
Number of participants with morbidity as measured by urgent transfers.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking urgent transfers
Time Frame
2-month follow up
Title
Number of participants with morbidity as measured by spasticity scores per usual care.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care
Time Frame
Admission
Title
Number of participants with morbidity as measured by spasticity scores per usual care.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care
Time Frame
4-weeks post injury
Title
Number of participants with morbidity as measured by spasticity scores per usual care.
Description
Observe the safety of using TINS during acute inpatient rehabilitation by prospectively tracking spasticity scores recorded per usual care
Time Frame
2-month follow-up
Secondary Outcome Measure Information:
Title
Number of participants with improved spasiticy scores as measured by PENN SPASM FREQUENCY SCALE (PSFS)
Description
Contains clinically relevant core questions concerning SCI-related pain. This is a 2 component self-report measure of the frequency of reported muscle spasms which is commonly used to quantify spasticity. Developed to augment clinical ratings of spasticity and provide a more comprehensive understanding of an individual's spasticity status. The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe". The second component is not answered if the person indicates they have no spasms in part. Lower scores indicate better outcomes.
Time Frame
Baseline
Title
Number of participants with improved spasiticy scores as measured by PENN SPASM FREQUENCY SCALE (PSFS)
Description
Contains clinically relevant core questions concerning SCI-related pain. This is a 2 component self-report measure of the frequency of reported muscle spasms which is commonly used to quantify spasticity. Developed to augment clinical ratings of spasticity and provide a more comprehensive understanding of an individual's spasticity status. The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe". The second component is not answered if the person indicates they have no spasms in part. Lower scores indicate better outcomes.
Time Frame
2-month follow-up
Title
Number of participants with decreased pain medication dosage compared at discharge and 2-month follow-up.
Description
Compare number of participants with decreased pain medication dosage at discharge and 2-month follow-up.
Time Frame
4-weeks post injury
Title
Number of participants with decreased pain medication dosage compared at discharge and 2-month follow-up.
Description
Compare number of participants with decreased pain medication dosage at discharge and 2-month follow-up.
Time Frame
2-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute tSCI paraplegia within 4 weeks of injury (n=22) 18-75 years old Neurologic levels T1-T10 English speaking Admitted to TIRR with pain medications TINS can elicit visible or palpable abdominal muscle contraction Exclusion Criteria: Subjects with pacemakers, defibrillators, insulin pumps, and similar devices History of peripheral neuropathy History of premorbid symptoms of peripheral neuropathy (numbness and/or tingling in the lower extremities, sharp/jabbing/burning pain in the lower extremities, sensitivity to touch, lack of coordination, lack of sensation, muscle weakness, etc.) History of nervous system disorder (i.e. prior SCI, stroke, brain injury, degenerative diseases such as Parkinson's disease, etc.) Ventilator dependent respiration Inability to speak Non-English speakers Pregnancy History of chronic pain Intolerant to electric stimulation Intolerant to the trial sessions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Argyrios Stampas, MD
Organizational Affiliation
UTHealth
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
15672627
Citation
Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma. 2004 Oct;21(10):1355-70. doi: 10.1089/neu.2004.21.1355.
Results Reference
background
PubMed Identifier
1748206
Citation
McNeill DL, Carlton SM, Hulsebosch CE. Intraspinal sprouting of calcitonin gene-related peptide containing primary afferents after deafferentation in the rat. Exp Neurol. 1991 Dec;114(3):321-9. doi: 10.1016/0014-4886(91)90158-9.
Results Reference
background
PubMed Identifier
3696474
Citation
McNeill DL, Hulsebosch CE. Intraspinal sprouting of rat primary afferents after deafferentation. Neurosci Lett. 1987 Oct 16;81(1-2):57-62. doi: 10.1016/0304-3940(87)90340-5.
Results Reference
background
PubMed Identifier
1728554
Citation
Diamond J, Foerster A. Recovery of sensory function in skin deprived of its innervation by lesion of the peripheral nerve. Exp Neurol. 1992 Jan;115(1):100-3. doi: 10.1016/0014-4886(92)90229-j. No abstract available.
Results Reference
background
PubMed Identifier
21387163
Citation
Gwak YS, Hulsebosch CE. Neuronal hyperexcitability: a substrate for central neuropathic pain after spinal cord injury. Curr Pain Headache Rep. 2011 Jun;15(3):215-22. doi: 10.1007/s11916-011-0186-2.
Results Reference
background
PubMed Identifier
30284350
Citation
Stampas A, Korupolu R, Zhu L, Smith CP, Gustafson K. Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. Neuromodulation. 2019 Aug;22(6):716-722. doi: 10.1111/ner.12855. Epub 2018 Oct 3.
Results Reference
background
PubMed Identifier
29249383
Citation
Hatch MN, Cushing TR, Carlson GD, Chang EY. Neuropathic pain and SCI: Identification and treatment strategies in the 21st century. J Neurol Sci. 2018 Jan 15;384:75-83. doi: 10.1016/j.jns.2017.11.018. Epub 2017 Nov 16.
Results Reference
background
PubMed Identifier
22547044
Citation
Ataoglu E, Tiftik T, Kara M, Tunc H, Ersoz M, Akkus S. Effects of chronic pain on quality of life and depression in patients with spinal cord injury. Spinal Cord. 2013 Jan;51(1):23-6. doi: 10.1038/sc.2012.51. Epub 2012 May 1.
Results Reference
background
PubMed Identifier
21539490
Citation
Johnson MI, Bjordal JM. Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain. Expert Rev Neurother. 2011 May;11(5):735-53. doi: 10.1586/ern.11.48.
Results Reference
background
PubMed Identifier
26949681
Citation
Ko EJ, Chun MH, Kim DY, Yi JH, Kim W, Hong J. The Additive Effects of Core Muscle Strengthening and Trunk NMES on Trunk Balance in Stroke Patients. Ann Rehabil Med. 2016 Feb;40(1):142-51. doi: 10.5535/arm.2016.40.1.142. Epub 2016 Feb 26.
Results Reference
background
PubMed Identifier
8192823
Citation
Nichols ME, Meador KJ, Loring DW, Poon LW, Clayton GM, Martin P. Age-related changes in the neurologic examination of healthy sexagenarians, octogenarians, and centenarians. J Geriatr Psychiatry Neurol. 1994 Jan-Mar;7(1):1-7. doi: 10.1177/089198879400700101.
Results Reference
background
Citation
https://www.nscisc.uab.edu/Public/Facts%202015.pdf
Results Reference
background
PubMed Identifier
16458733
Citation
Dubeau CE. The aging lower urinary tract. J Urol. 2006 Mar;175(3 Pt 2):S11-5. doi: 10.1016/S0022-5347(05)00311-3.
Results Reference
background
Citation
http://www.emsci.org/index.php/project/the-project/time-schedule
Results Reference
background
PubMed Identifier
11135383
Citation
Chartier-Kastler EJ, Denys P, Chancellor MB, Haertig A, Bussel B, Richard F. Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourol Urodyn. 2001;20(1):61-71. doi: 10.1002/1520-6777(2001)20:13.0.co;2-d.
Results Reference
background
PubMed Identifier
23069382
Citation
Bellucci CH, Wollner J, Gregorini F, Birnbock D, Kozomara M, Mehnert U, Schubert M, Kessler TM. Acute spinal cord injury--do ambulatory patients need urodynamic investigations? J Urol. 2013 Apr;189(4):1369-73. doi: 10.1016/j.juro.2012.10.013. Epub 2012 Oct 12.
Results Reference
background
PubMed Identifier
15613958
Citation
Buchele G, Och B, Bolte G, Weiland SK. Single vs. double data entry. Epidemiology. 2005 Jan;16(1):130-1. doi: 10.1097/01.ede.0000147166.24478.f4. No abstract available.
Results Reference
background
PubMed Identifier
21812906
Citation
Verrills P, Vivian D, Mitchell B, Barnard A. Peripheral nerve field stimulation for chronic pain: 100 cases and review of the literature. Pain Med. 2011 Sep;12(9):1395-405. doi: 10.1111/j.1526-4637.2011.01201.x. Epub 2011 Aug 3.
Results Reference
background
PubMed Identifier
25240665
Citation
Petersen EA, Slavin KV. Peripheral nerve/field stimulation for chronic pain. Neurosurg Clin N Am. 2014 Oct;25(4):789-97. doi: 10.1016/j.nec.2014.07.003. Epub 2014 Aug 15.
Results Reference
background

Learn more about this trial

Transcutaneous Intercostal Nerve Stimulation in Spinal Cord Injury

We'll reach out to this number within 24 hrs